VG Life Sciences Inc. (VGLS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.46 Million USD | 14.39% |
| 2022 | 2.16 Million USD | 97.96% |
| 2021 | -1.16 Million USD | 1.86% |
| 2020 | -1.18 Million USD | -3548.97% |
| 2019 | 34.4 Thousand USD | 0.0% |
| 2018 | 34.4 Thousand USD | 0.0% |
| 2017 | 34.4 Thousand USD | 105.79% |
| 2016 | -594.5 Thousand USD | 0.0% |
| 2014 | - USD | -6.04% |
| 2013 | -3.9 Million USD | -91798.35% |
| 2012 | -2.57 Million USD | 0.0% |
| 2006 | -6.37 Million USD | 6.77% |
| 2005 | -4.44 Million USD | 48.76% |
| 2004 | -7.52 Million USD | -107.94% |
| 2003 | -3.94 Million USD | -247.58% |
| 2002 | -1.17 Million USD | -37.53% |
| 2001 | -897.01 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -3195.00 USD | -100.13% |
| 2024 Q1 | -6240.00 USD | 193.43% |
| 2023 Q1 | -4070.00 USD | 76.86% |
| 2023 Q2 | -8910.00 USD | -118.92% |
| 2023 Q4 | -5660.00 USD | -232.94% |
| 2023 Q3 | -1700.00 USD | 80.92% |
| 2023 FY | - USD | 14.39% |
| 2022 Q3 | -3920.00 USD | 0.0% |
| 2022 Q1 | -2250.00 USD | 35.71% |
| 2022 FY | - USD | 97.96% |
| 2022 Q4 | -17.59 Thousand USD | -348.72% |
| 2021 FY | - USD | 1.86% |
| 2021 Q4 | -3500.00 USD | 99.65% |
| 2021 Q3 | -1 Million USD | -520.58% |
| 2021 Q2 | -161.14 Thousand USD | 0.0% |
| 2020 FY | - USD | -3548.97% |
| 2019 FY | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2017 FY | - USD | 105.79% |
| 2016 FY | - USD | 0.0% |
| 2015 Q3 | -644.44 Thousand USD | 12.83% |
| 2015 Q2 | -739.26 Thousand USD | 7.76% |
| 2015 Q1 | -801.48 Thousand USD | -48.02% |
| 2014 Q1 | -1.65 Million USD | 22.62% |
| 2014 Q2 | -1.15 Million USD | 30.27% |
| 2014 Q3 | -798.77 Thousand USD | 30.65% |
| 2014 FY | - USD | -6.04% |
| 2014 Q4 | -541.45 Thousand USD | 32.21% |
| 2013 Q2 | 61.57 Thousand USD | 3284.0% |
| 2013 Q3 | -853.63 Thousand USD | -1486.31% |
| 2013 Q4 | -2.13 Million USD | -150.05% |
| 2013 Q1 | -1933.92 USD | 0.0% |
| 2013 FY | - USD | -91798.35% |
| 2012 FY | - USD | 0.0% |
| 2007 Q1 | -1.24 Million USD | -60.36% |
| 2007 Q2 | -785.43 Thousand USD | 37.1% |
| 2007 Q3 | -795.35 Thousand USD | -1.26% |
| 2006 Q2 | -1.7 Million USD | 47.79% |
| 2006 FY | - USD | 6.77% |
| 2006 Q4 | -778.71 Thousand USD | -50.47% |
| 2006 Q3 | -517.5 Thousand USD | 69.64% |
| 2006 Q1 | -3.26 Million USD | -106.69% |
| 2005 Q1 | -1.11 Million USD | 15.2% |
| 2005 Q3 | -606.99 Thousand USD | 40.91% |
| 2005 Q2 | -1.02 Million USD | 8.04% |
| 2005 Q4 | -1.57 Million USD | -160.18% |
| 2005 FY | - USD | 48.76% |
| 2004 FY | - USD | -107.94% |
| 2004 Q1 | -1.64 Million USD | 12.53% |
| 2004 Q2 | -4.43 Million USD | -170.12% |
| 2004 Q3 | -1.07 Million USD | 75.85% |
| 2004 Q4 | -1.31 Million USD | -23.09% |
| 2003 FY | - USD | -247.58% |
| 2003 Q4 | -1.91 Million USD | -151.23% |
| 2003 Q1 | -155.14 Thousand USD | -152.65% |
| 2003 Q3 | -715.86 Thousand USD | 46.87% |
| 2003 Q2 | -1.41 Million USD | -256.13% |
| 2002 Q3 | -743.24 Thousand USD | -451.23% |
| 2002 Q2 | -143.55 Thousand USD | 10.97% |
| 2002 Q1 | -159.8 Thousand USD | 77.82% |
| 2002 FY | - USD | -37.53% |
| 2002 Q4 | -166.94 Thousand USD | 78.67% |
| 2001 FY | - USD | 0.0% |
| 2001 Q4 | -672.71 Thousand USD | -21378.86% |
| 2001 Q3 | -3132.00 USD | -101.07% |
| 2001 Q1 | -33.65 Thousand USD | 11.04% |
| 2001 Q2 | 292.19 Thousand USD | 1012.07% |
| 2000 Q4 | -37.03 Thousand USD | 40.38% |
| 2000 Q3 | -55.39 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 96.534% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 58.476% |
| SQZ Biotechnologies Company | -64.14 Million USD | 96.162% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 85.827% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 102.618% |
| Mesoblast Limited | -62.38 Million USD | 96.054% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -60.277% |
| Genus plc | 73.7 Million USD | 103.34% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 62.763% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 30.591% |
| Marizyme, Inc. | -34.28 Million USD | 92.818% |
| ContraFect Corporation | -64.99 Million USD | 96.212% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 71.934% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 45.607% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -75.625% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 6.902% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -5.943% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -375.234% |
| Accustem Sciences Inc. | -3.74 Million USD | 34.286% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 94.895% |
| EV Biologics, Inc. | -1.26 Million USD | -94.292% |
| Q BioMed Inc. | -617.62 Thousand USD | -298.611% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 168.923% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -289.296% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -7.767% |
| Biomind Labs Inc. | -1.03 Million USD | -137.972% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 124.926% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 65.622% |
| Skye Bioscience, Inc. | -13.54 Million USD | 81.827% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -65.518% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -9747.728% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 36.619% |
| IMV Inc. | -35.52 Million USD | 93.07% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 84.487% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 1.6% |
| GB Sciences, Inc. | -1.41 Million USD | -73.39% |
| Alpha Cognition Inc. | -9.7 Million USD | 74.634% |
| HST Global, Inc. | -5303.00 USD | -46325.269% |
| CSL Limited | 4.78 Billion USD | 100.051% |
| Halberd Corporation | -74.27 Thousand USD | -3214.439% |
| Enzolytics Inc. | -2.12 Million USD | -16.018% |
| Resverlogix Corp. | -11.74 Million USD | 79.033% |
| Affymax, Inc. | -14.29 Million USD | 82.778% |
| SYBLEU INC | -141.57 Thousand USD | -1639.009% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 19.624% |
| argenx SE | -216.02 Million USD | 98.86% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 95.551% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 302.295% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -64.249% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 749.854% |
| AVAX Technologies, Inc. | -6.11 Million USD | 59.724% |
| Zenith Capital Corp. | -8.6 Million USD | 71.393% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.01% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -14031.979% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -0.632% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -1298.631% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 93.789% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 14.881% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -135.296% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 36714.099% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -40.682% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -28.165% |
| BioStem Technologies, Inc. | -7.55 Million USD | 67.407% |
| ONE Bio Corp. | 13.61 Million USD | 118.085% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -1259.522% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -19.686% |
| Agentix Corp. | -1.37 Million USD | -79.473% |
| LadRx Corporation | 412.28 Thousand USD | 697.146% |
| Cell Source, Inc. | -4.27 Million USD | 42.378% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -570.422% |
| Regen BioPharma, Inc. | 1.46 Million USD | 267.94% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -162.761% |
| NovAccess Global Inc. | -1.03 Million USD | -137.914% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 127.806% |
| Itoco Inc. | -1.86 Million USD | -31.725% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -548.525% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -120.603% |
| Kadimastem Ltd | -2.62 Million USD | 6.19% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -929.451% |
| CytoDyn Inc. | -18.02 Million USD | 86.345% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -3015.226% |
| Mobile Lads Corp. | -2.24 Million USD | -9.851% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -20031.916% |
| Qrons Inc. | -40.08 Thousand USD | -6042.392% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -406.906% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 566.776% |
| Rebus Holdings, Inc. | -951 Thousand USD | -158.878% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -131.818% |
| International Stem Cell Corporation | 202 Thousand USD | 1318.778% |
| Bioxytran, Inc. | -3.82 Million USD | 35.554% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -4576.922% |
| Cardax, Inc. | - USD | Infinity% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 93.136% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -5370.96% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 10.083% |
| Neutra Corp. | -181.24 Thousand USD | -1258.33% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 87.787% |
| PureTech Health plc | -11.62 Million USD | 78.826% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 87.787% |
| IXICO plc | -707 Thousand USD | -248.222% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 67.964% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 94.908% |
| CSL Limited | 4.73 Billion USD | 100.052% |
| Cellectis S.A. | -92.63 Million USD | 97.342% |